Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes - Report - MDSpire
Advertisement
Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes
Clinical Report: Significant and Reversible Increases in Circulating IGF-1 During Teprotumumab N01 Therapy
Overview
This study evaluates the dynamics of circulating insulin-like growth factor-1 (IGF-1) in patients with moderate-to-severe thyroid eye disease (TED) treated with teprotumumab N01. It finds significant increases in IGF-1 levels during treatment, which are reversible post-therapy.
Background
Thyroid eye disease (TED) is an autoimmune condition that can severely impact patients' quality of life. The introduction of IGF-1 receptor inhibitors like teprotumumab has transformed TED management, yet the effects on circulating IGF-1 remain poorly understood.
Data Highlights
Parameter
Baseline
Post-Treatment Peak
Fold Change
Serum IGF-1
151.0 ng/mL (IQR 116.8–187.3)
649.5 ng/mL (IQR 520.8–753.8)
4.2 (IQR 3.5–5.0)
HbA1c
-
0.40% (IQR 0.20–0.77)
-
GA
-
1.63% (IQR 0.95–2.39)
-
FBG
-
0.65 mmol/L (IQR 0.30–1.14)
-
Key Findings
Teprotumumab N01 treatment led to a median peak IGF-1 concentration of 649.5 ng/mL, a 4.2-fold increase from baseline.
IGF-1 levels remained elevated for up to 3 months post-treatment before declining towards baseline.
Glycemic markers showed modest increases, with HbA1c rising by a median of 0.40% from baseline.
Patients with baseline dysglycemia experienced more pronounced glycemic deterioration.
IGF-1 dynamics were not independent correlates of glycemic changes after adjusting for confounding factors.
Clinical Implications
The study reports significant increases in IGF-1 levels during teprotumumab therapy for TED, with limited association to glycemic changes.
Conclusion
Teprotumumab N01 is associated with significant increases in circulating IGF-1, which are reversible after treatment.
